Investigation of intracellular signalling events mediating the mechanism of action of 7-hydroxycoumarin and 6-nitro-7-hdroxycoumarin in human renal cells

Cancer Letters

Volumn 205, Issue 1, 2004, Pages 69-79

  Finn, Gregory J ^a   Creaven, Bernadette S ^a   Egan, Denise A ^a  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

6 Nitro 7 hydroxycoumarin; In vitro; Mitogen activated protein kinase; Renal cell carcinoma

Indexed keywords

6 NITRO 7 HYDROXYCOUMARIN; COUMARIN DERIVATIVE; DNA TOPOISOMERASE; GLYCOPROTEIN P; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; UMBELLIFERONE; UNCLASSIFIED DRUG; VINBLASTINE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 1242293659     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.09.024     Document Type: Article

References (61)

1. Murray R.D., Mendez J., Brown S.A. The Natural Coumarins: Occurrence, Chemistry and Biochemistry. 1982;Wiley, UK. pp. 1-12.
2. Egan D.A., O'Kennedy R., Moran E., Thornes R.D. The pharmacology, metabolism, analysis and applications of coumarin and coumarin related compounds. Drug. Metab. Rev. 22:(5):1990;503-529.
3. Kolodziej H., Kayser O., Woerdenbag H.J., Van Ulden W., Pras N. Structure-cytotoxicity relationships of a series of natural and semi-synthetic simple coumarins as assessed in two human tumour cell lines. Naturforshung. 52:1997;240-244.
4. Jimenez-Orozco F.A., Molina-guarneros J.A., Mendoza-patino N., Leon-cedeno F., Flores-perez B., Santos-santos E., Mandoki J.J. Cytostatic activity of coumarin metabolites and derivatives in the B-16-F10 murine melanoma cell line. Melanoma Res. 9:1999;243-247.
5. Finn G.J., Creaven B., Egan D. Study of the in vitro potential of natural and synthetic coumarin derivatives, using human normal and neoplastic skin cell lines. Melanoma Res. 11:2001;461-467.
6. Laurin P., Klich M., Dupis-Hamelin C., Mauvais P., Lassaigne P., Bonnefoy A., Musicki B. Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B. Bioorg. Med. Chem. Lett. 9:1999;2079-2084.
7. Hoult J.R.S., Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmac. 27:(4):1996;713-722.
8. Pillai S.P., Menon S.R., Mitscher L.A., Pillai C.A., Shankel D.A. Umbelliferone analogues and their potential to inhibit benzo(a)pyrene and hydrogen peroxide induced mutations. J. Nat. Prod. 62:1999;1358-1362.
9. Kimura Y., Okuda H., Arichi S., Baba K., Kozawa M. Inhibition of the formation of 5-hydroxy-6, 8, 11, 14-eicosatetraenoic acid from arachidonic acid in polymorphonuclear leukocytes by various coumarins. Biochim. Biophys. Acta. 834:1985;224-229.
10. Hoffmanova J., Kozubik A., Dusek L., Pachernik J. Inhibitors of lipoxygenase metabolism exert synergistic effects with retinoic acid on differentiation of human leukaemia HL-60 cells. Eur. J. Pharmacol. 350:1998;273-284.
11. Maucher A., Kager M., von Angerer E. Evaluation of the anti-tumour activity of coumarin in prostrate cancer models. J. Clin. Res. Clin. Oncol. 119:1993;150-154.
12. Sharma S., Stutzman D., Kellof J.G., Steele V.E. Screening of potential chemo-preventive agents using biochemical markers of carcinogenesis. Cancer Res. 54:1994;5848-5855.
13. Egan D., James P., Cooke D., O'Kennedy R. Studies on the cytostatic and cytotoxic effects and mode of action of 8-nitro-7-hydroxycoumarin. Cancer Lett. 118:1997;201-211.
14. Hayes J.D., Pulford D.J., Ellis E.M., McLeod R., James R.F.L., Seidegard J., et al. Regulation of rat glutathione S-transferase A5 by cancer chemo-preventative agents: mechanisms of inducible resistance to aflatoxin B1. Chemico-Biological Inter. 111-112:1998;51-67.
15. Marshall E.M., Riley L.K., Rhoades J., Eichnorm T., Jennings C.D., Cibule M., Thompson J. Effects of coumarin (1,2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells and monocytes in patients with advanced malignancies. J. Biol. Response Mod. 8:(1):1989;62-69.
16. Marshall E.M., Mendleson L., Butler K., Riley L., Cantress J., Wiseman C., et al. Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetadine: a pilot study. J. Clin. Oncol. 5:(6):1987;862-866.
17. Dexeus F.H., Logothetis C.J., Sella A., Fitz K., Amoto R., Reuben J.M., Dozier N. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 8:(2):1990;325-329.
18. Marshall M.E., Ryles M., Butler K., Weiss L. Treatment of advanced renal cell carcinoma (RCC) with coumarin and cimetidine: long-term follow-up of patients treated on a phase I trial. J. Cancer Res. Clin. Oncol. 120:1994;535-538.
19. Kokron O., Baugmeyer G., Theyer G., Maca S., Gasser G., Schmidt P.R., Pfluger H. Cimetidine and coumarin treatment of metastatic renal cell carcinoma. Oncology. 48:(2):1991;102-106.
20. Conley D., Marshall M.E. Effects of coumarin on human tumour cell growth and cell cycle analysis in vitro. Proc. Am. Assoc. Cancer Res. 28:1987;63.
21. Marshall M.E., Kervin K., Benfield C., Umerani A., Albainy-Jenei S., Zhao Q., Khazaeli B. Growth inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro. J. Cancer Res. Clin. Oncol. 120:(1):1994;S3-S10.
22. Finn G.J., Kenealy E., Creaven B.S., Egan D.A. In vitro cytotoxic potential and mechanism of action of selected coumarins, using human renal cell lines. Cancer Lett. 183:2002;61-68.
23. Cobb M.H. MAP kinase pathways. Prog. Biophys Mol. Biol. 71:1999;479-500.
24. Cross T.G., Scheel-Toellner D., Henrequiz N.V., Deacon E., Salmon M., Lord J.M. Serine/threnoine protein kinases and apoptosis. Exp. Cell. Res. 256:2000;34-41.
25. Bourbon N.A., Yun J., Kester M. Ceramide directly activates protein kinase C to regulate a stress-activated protein kinase signalling complex. J. Biol. Chem. 275:(45):2000;35617-35623.
26. Englaro W., Rezzonic R., Durand-clement M., Lallemand D., Ortonne J.P., Bollotti R. Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J. Biol. Chem. 270:(41):1995;24315-24320.
27. Smalley K., Eisen T. The involvement of P38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. Fed. Eur. Biochem. Soc. Lett. 476:2000;198-202.
28. Malek Z., Swope V., Suzuki I., Akali C., Harriger M.D., Boyces S.T., et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melantrophic peptides. Proc. Natl Acad. Sci. USA. 92:1995;1789-1793.
29. Busca R., Berlotto J., Ballotti R. Inhibition of the phosphatidylinositol 3-kinase/p70s6-kinase pathway induces B16 melanoma cell differentiation. J. Biol. Chem. 271:(50):1976;31824-31830.
30. Englaro W., Berlotto C., Busca R., Brunet A., Pages G., Ortonne J., Ballotti R. Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J. Biol. Chem. 273:(16):1998;9966-9970.
31. Cuenda A., Cohen P. Stress activated protein kinase, p38 and a rapamycin sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 274:1999;4341-4346.
32. Engelman J.A. Constitutively active mitogen-activated protein kinase kinase 6 or salicylate induces 3T3 L1 adipogenesis. J. Biol. Chem. 274:1999;35630-35638.
33. Park H.E., Gilchrest B.A. Signalling pathways mediating melanogenesis. Cell. Mol. Biol. 45:(7):1999;919-930.
34. Nebreda A.R. p38 MAP kinases: beyond the stress responses. Trends Biochem. Sci. 25:2000;257-260.
35. Hagemann C., Blank J. The ups and downs of MEK kinase interactions. Cell. Signal. 13:2001;863-875.
36. Ozaki I., Tani E., Ikemoto H., Kitagawa H., Fujikawa H. Activation of stress-activated protein kinase c-jun terminal kinase and p38 kinase in calphostin c induced apoptosis requires caspase-3 -like proteases but is dispensable for cell death. J. Biol. Chem. 7:(9):1999;5310-5317.
37. Fan M., Du L., Stone A.A., Gilbert K., Chambers T.C. Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2M. Cancer Res. 60:2000;6403-6407.
38. MacKeigan J.P., Collins T.S., Ting J.P.Y. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem. 275:(50):2000;38953-38956.
39. Dent P., Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal pathway: potential role in promoting cytotoxic drug action. Clin. Cancer Res. 7:2001;775-783.
40. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
41. Lorico A., Long B.H. Biochemical characterisation of elasamicin and other coumarin-related antitumor agents as potent inhibitors of human topoisomerase II. Eur. J. Cancer. 29A:(14):1993;1985-1993.
42. Hamilton C., Winker M., Louie K., Batist G., Behrens B., Tsuruo T., et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharm. 34:1985;2583-2586.
43. Finn G., Creaven B., Egan D. In vitro cytotoxic potential and mechanism of action of selected coumarins, using human renal cell lines. Cancer Lett. 183:2002;61-68.
44. Carmichael J., DeGraff G., Gazdar A., Minna J., Mitchell J. Evaluation of a tetrazolium-based colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942.
45. Doige C.A., Sharom F.J. Strategies for the purification of P-glycoprotein from multi-drug resistant Chinese ovary cells. Protein Exp. Purific. 2:1991;256-265.
46. Lewis T.S., Shapiro P., Ahn N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74:1998;49-139.
47. Stadheim T.A., Xiao H., Eastmann A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated Ml-1 cells. Cancer Res. 61:2001;1533-1540.
48. Motzer R.J., Bander N.H., Nanus D.N. Renal-cell carcinoma. N. Engl. J. Med. 335:1996;865-875.
49. Oka H., Chatani Y., Hoshino R., Ogawa O., Kakehi Y., Terachi T., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55:1995;4182-4187.
50. Ozaki I., Tani E., Ikemoto H., Kitagawa H., Fujikawa H. Activation of stress-activated protein kinase c-jun terminal kinase and p38 kinase in calphostin c induced apoptosis requires caspase-3 -like proteases but is dispensable for cell death. J. Biol. Chem. 7:(9):1999;5310-5317.
51. Finn G.J., Creaven B.S., Egan D.A. Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase. Biochem. Pharm. 2003;. (in press).
52. Adler V., Yin Z., Fuchs S.Y., Berenza M., Rosario L., Tew K.D., et al. Regulation of JNK signalling. Eur. Mol. Biol. Org. J. 18:1999;1321-1334.
53. Huff A., Kreuzer K.N. Evidence for a common mechanism of action of antitumour and antibacterial agents that inhibit type II topoisomerases. J. Biol. Chem. 265:1990;20496-20505.
54. Martin-Cordero C., Lopez-Lazaro M., Pinero M., Pinero J., Ortiz T., Cortes F., Ayuso M.J. Gluosylated isoflazones as DNA topoisomerase II poisons. J. Enzyme Inhib. 15:2000;455-460.
55. Fortune J.M., Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase II by blocking DNA cleavage. J. Biol. Chem. 273:(28):1998;17643-17650.
56. Marshall M.E., Kervin K., Benfield C., Umerani A., Albainy-jenei S., Zhao Q., Hhazaeli B. Growth inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro. J. Cancer Res. Clin. Oncol. 120:(1):1994;S3-S10.
57. Champoux J.J. DNA topoisomerases: structure, function and mechanism. Annu. Rev. Biochem. 70:2001;369-413.
58. Stefanelli C., Tantini B., Fattori M., Stanic I., Pignatti C., Clo G., et al. Caspase activation in etoposide-treated fibroblasts is correlated to ERK phosphorylation and both events are blocked by polyamine depletion. Fed. Eur. Biochem. Soc. Lett. 527:2002;223-228.
59. Tian W., Zhang Z., Cohen D.M. Tian, MAPK signaling and the kidney. Am. J. Renal Physiol. 279:2000;F593-F604.
60. Goldstein L.J., Galski H., Fojo A., Willingham M., Lai S., Gadzar A., et al. Expression of a multi-drug resistance gene in human cancers. Natl. Cancer Inst. 81:1989;116-124.
61. Finn G.J., Creaven B.S., Egan D.A. Modulation of mitogen-activated protein kinases by 6-nitro-7-hydroxycoumarin, mediates apoptosis in renal carcinoma cells. Eur. J. Pharm. 2003;. (in press).